OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Virus Eradication is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?	172
Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, I	59
Impact of COVID-19 on people living with HIV: A review	57
Minimum costs to manufacture new treatments for COVID-19	54
Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19	35
Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries	23
A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection	20
Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic	19
Altruism: Scoping review of the literature and future directions for HIV cure-related research	14
Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers	13
Impact of COVID-19 and intensive care unit capacity on vaccination support: Evidence from a two-leg representative survey in the United Kingdom	11
Towards the elimination of viral hepatitis in Thailand by the year 2030	11
Langya virus outbreak in China, 2022: Are we on the verge of a new pandemic?	9
A viewpoint: The 2022 monkeypox outbreak	9
Willingness to risk death endpoint in HIV cure-related research with otherwise healthy volunteers is misleading	9
Achievements and gaps to provide pre-exposure prophylaxis (PrEP) for women across the European Region – Results from a European survey study	9
Re-examining the HIV ‘functional cure’ oxymoron: Time for precise terminology?	8
Antiviral strategies targeting herpesviruses	7
A landscape analysis of HIV cure-related clinical research in 2019	7
HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper	7
Characteristics of suboptimal immune response after initiating antiretroviral therapy among people living with HIV with a pre-treatment CD4 T cell count <200 cells/mm3 in Thailand	7
Vaccination with inactivated virus against low pathogenic avian influenza subtype H9N2 does not prevent virus transmission in chickens	6
Time for revolution? Enhancing meaningful involvement of people living with HIV and affected communities in HIV cure-focused science	6
Motivations, barriers and experiences of participants in an HIV reservoir trial	6
Differences in HIV burden in the inflamed and non-inflamed colon from a person living with HIV and ulcerative colitis	6

‘Informed and empowered’: a mixed-methods study of crowdsourcing contests to promote uptake of HIV self-testing kits among African Americans	6
Bringing social context into global biomedical HIV cure-related research: An urgent call to action	5
The perceived impact of an HIV cure by people living with HIV and key populations vulnerable to HIV in the Netherlands: A qualitative study	5
The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV	5
Hepatitis B birth dose vaccination for newborns in Uganda: A qualitative inquiry on pregnant women's perceptions, barriers and preferences	5
Hepatitis C in Uganda: Identification of infected blood donors for micro-elimination	5
Efficacy of the hepatitis B vaccine alone in the prevention of hepatitis B perinatal transmission in infants born to hepatitis B e antigen-negative carrier mothers	5
Comparison of methods to quantify inducible HIV-1 outgrowth	5
Prevention and control measures significantly curbed the SARS-CoV-2 and influenza epidemics in China	5
Unwillingness of patients in Ghana to interrupt antiretroviral therapy for HIV cure research	5
Host-directed therapy with 2-deoxy-D-glucose inhibits human rhinoviruses, endemic coronaviruses, and SARS-CoV-2	4
A cohort analysis of sexually transmitted infections among different groups of men who have sex with men in the early era of HIV pre-exposure prophylaxis in France	3
Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir	3
Expanding reimbursement of immediate treatment using direct acting antivirals to reduce hepatitis C incidence among HIV positive men who have sex with men in Bangkok, Thailand: A cost effectiveness mo	3
Hypothetical questionnaires may overestimate willingness to participate in HIV cure research: Comparison of a cross-sectional survey to actual willingness to participate in an HIV cure study in the Ne	3
Bispecific antibody-derived molecules to target persistent HIV infection	3
Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection	3
The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review	3
A systematic review of limiting antigen avidity enzyme immunoassay for detection of recent HIV-1 infection to expand supported applications	3
Adeno-associated virus-vectored delivery of HIV biologics: the promise of a “single-shot” functional cure for HIV infection	3
Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection	3
Substantial uneven proliferation of CD4+ T cells during recovery from acute HIV infection is sufficient to explain the observed expanded clones in the HIV reservoir	3
Persistent HIV-1 transcription in CD4+ T cells from ART-suppressed individuals can originate from biologically competent proviruses	3
Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV	2
Combination strategies to durably suppress HIV-1: Soluble T cell receptors	2
Adaptation of the intact proviral DNA assay to a nanowell-based digital PCR platform	2
Treatment and monitoring of children and adolescents with hepatitis C in Russia: Results from a multi-centre survey on policy and practice	2
Impact of hepatitis B vaccination programs in Vietnam evaluated by estimating HBsAg prevalence	2
Menopause care in women living with HIV in the UK - A review	2
Identification of a pharmacological approach to reduce ACE2 expression and development of an in vitro COVID-19 viral entry model	2
High prevalence of gastrointestinal manifestations among Cytomegalovirus end-organ disease in the combination antiretroviral era	2
Antiviral activity of nitazoxanide against Morbillivirus infections	2
Is the human T-cell lymphotropic virus type 2 in the process of endogenization into the human genome?	2
Highlights from the Tenth International Workshop on HIV Persistence during Therapy, December 13-16, 2022, Miami, Florida-USA	2
OP 3.4 – 00197 Infected naïve CD4+ T cells in children with HIV can proliferate and persist on ART	2
Heat shock protein: a double-edged sword linking innate immunity and hepatitis B virus infection	2
Phylogenetic signature and prevalence of natural resistance-associated substitutions for hepatitis C virus genotypes 3a and 3b in southwestern China	2
Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: a systematic review of in vitro studies	2
OP 3.7 – 00099 Cohort-specific Adaptation of the Intact Proviral DNA Assay (IPDA) to HIV-1 subtypes A1, D, and recombinants	2
Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium	1
OP 3.2 – 00056 Clonally expanded HIV-1 proviruses with 5′-Leader defects can give rise to nonsuppressible residual viremia and complicate ART management	1
No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach	1
OP 1.7 – 00194 Potent latency reversal enables in-depth transcriptomic analysis of the translation-competent HIV-1 reservoir	1
Key highlights from the international AIDS society (IAS) conference 2021	1
OP 8.3 – 00028 HIV-vaccine induced, broad and polyfunctional CD4 and CD8 T cell responses are associated with prolonged time off ART and lower pVL at the end of ATI in the AELIX-002 therapeutic vaccin	1
Intact provirus and integration sites analysis in acute HIV-1 infection and changes after one year of early antiviral therapy	1
OP 6.6 – 00134 Viral Suppression in SHIV-infected Rhesus Macaques following AAVmediated Delivery of Closer-to-germline Monoclonal Antibodies	1
OP 5.3 – 00082 1-year treatment with ponatinib provides protection of CD4+T cells against HIV that is maintained at least 1 year more after treatment interruption	1
OP 7.3 – 00139 Pre-treatment Interruption Plasma Metabolites and Glycans Correlate with Time to HIV Rebound and Reservoir Size in ACTG A5345	1
OP 6.2 – 00195 Targeted genome engineering of human t cells in vivo for HIV cure	1

Hepatitis B prevalence and associated factors in adults presenting for infection screening in northern Thailand	1
OP 3.3 – 00030 Inducible replication-competent HIV proviruses persist in memory CD4+ T cells expressing high levels of the integrin VLA-4 (α4β1)	1
OP 5.2 – 00070 Characterization of a dual PTPN1/PTPN2 inhibitor to target latent HIV reservoirs	1
Commentary title: COVID-19 research, Africa, and global health	1
OP 6.1 It's a mountain not a hill: Progress made in realizing AAV-delivered inhibitors for an HIV cure	1
OP 8.6 – 00166 Autologous neutralizing antibody responses in bnAb-treated rhesus macaques	1
Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting	1
OP 7.4 – 00012 Series of Jojo. A way to disseminate HIV Cure information in a community language	1
Influenza A (H6N6) viruses isolated from chickens replicate in mice and human lungs without prior adaptation	1
Reversibility of some oxidative stress markers in chronic hepatitis C patients after receiving direct-acting antiviral agents	1
OP 3.1 HIV Persistence in women, an update	1
OP 2.8 – 00193 Enhancing PKC Modulator HIV Latency Reversing Agents	1
OP 1.8 – 00204 Romidepsin in combination with the BCL-2 antagonist venetoclax synergistically reduce the size of the HIV reservoir	1
Sulforaphane prevents the reactivation of HIV-1 by suppressing NFκB signaling	1
OP 8.2 – 00033 Interleukin-2 administration is a potent latency reversal agent in people with treated HIV infection	1
OP 1.3 – 00017 The fraction of cells with unspliced HIV RNA is not associated with plasma viremia	1
OP 1.2 – 00157 HIV Silencing and Cell Survival Signatures of HIV-Infected CD4 T Cell Transcriptomes under Antiretroviral Therapy (ART)	1
OP 3.6 – 00023 Effect of HIV-1 infection, viral particle production, and proviral integration site on CD4+ T cell proliferation	1
Summary of the coronavirus disease 2019 (COVID-19) update from the 2020 Conference on Retroviruses and Opportunistic Infections, 8–11 March 2020, Boston, USA	1
OP 3.8 – 00066 Characterization of the HIV-1 viral reservoir in subtype B early treated individuals	1
OP 1.10 – 00210 Clonal Dynamics within HIV-Infected CD4 T Cell Reservoirs after PD-1 Blockade under ART	1
The ethical case for placebo control in HIV-cure-related studies with ART interruption	1
OP 8.5 – 00104 TGF-beta Blockade to Stop HIV White Noise: a New “Release and Kill” HIV Strategy	1
OP 8.4 – 00165 TLR agonist and SIV mAbs administered to SIV-infected ART-suppressed macaques did not delay rebound after treatment interruption	1
Cascade of care among hepatitis B patients in Maastricht, the Netherlands, 1996 to 2018	1
OP 6.8 – 00102 In vivo evolution of env in SHIV-AD8-infected rhesus macaques after AAV-eCD4-Ig therapy	1
The HIV-2 OGH double reporter virus shows that HIV-2 is less cytotoxic and less sensitive to reactivation from latency than HIV-1 in cell culture	1
Rate of occult hepatitis B virus infection among individuals with tuberculosis in northeastern Iran: A molecular epidemiological study	1
OP 1.9 – 00042 Measuring the impact of early 3BNC117 intervention at ART initiation on the productive reservoir in a cohort of diverse viral subtypes: results from the VIP-SPOT assay in the eCLEAR tri	1
OP 1.1 Sequencing HIV: Significance and Impact	1
OP 1.5 – 00046 P400/Tip60 chromatin remodeling complex in HIV transcription and latency establishment	1
OP 3.5 – 00152 HIV-1RNA+infected CD4 T cell burden in acute HIV-1 infection and association with inflammatory markers	1
OP 7.2 – 00035 Impact of 10-1074LS and 3BNC117-LS on viral rebound dynamics following treatment interruption six months after dosing: four cases from the open label arm of the RIO trial	1
OP 6.3 – 00150 Delivery and long-term expression of CCR5-blocking monoclonal antibody Leronlimab with AAV for ART-free remission from SHIV viremia	1
Patient acceptability of, and attitudes towards, hepatitis B cure research – A scoping review and identification of knowledge gaps	1
Interrupting antiretroviral therapy in HIV cure trials during COVID-19: Adaptation to low transmission settings	1
OP 6.4 – 00096 High-efficiency CRISPR/Cas9-mediated disruption of ccr5 in human hematopoietic stem progenitor cells generates HIV-refractory immune systems	1
Barriers that prevent adults living with HBV infection from participating in clinical research: experience from South Africa	1
HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens	1
OP 1.6 – 00138 Role of UHRF1 in HIV-1 transcriptional repression through epigenetic and non-epigenetic mechanisms	1
Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral	1
OP 6.7 – 00044 Long-term ART-free SIV Remission Following Allogeneic Hematopoietic Cell Transplantation in Mauritian Cynomolgus Macaques	1
OP 1.4 – 00053 Definitive evidence of a persistent HIV reservoir in human brain myeloid cells despite ART	1